Cargando…

Advent of CRISPR Based Immunotherapy in Hematologic Malignancies

Detalles Bibliográficos
Autores principales: Perez, RK, Chen, R, Kang, R, Perez, AR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018007/
https://www.ncbi.nlm.nih.gov/pubmed/29953127
_version_ 1783334871847927808
author Perez, RK
Chen, R
Kang, R
Perez, AR
author_facet Perez, RK
Chen, R
Kang, R
Perez, AR
author_sort Perez, RK
collection PubMed
description
format Online
Article
Text
id pubmed-6018007
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-60180072018-06-25 Advent of CRISPR Based Immunotherapy in Hematologic Malignancies Perez, RK Chen, R Kang, R Perez, AR J Oncopathol Clin Res Article 2018-03-30 2018 /pmc/articles/PMC6018007/ /pubmed/29953127 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Perez, RK
Chen, R
Kang, R
Perez, AR
Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title_full Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title_fullStr Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title_full_unstemmed Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title_short Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
title_sort advent of crispr based immunotherapy in hematologic malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018007/
https://www.ncbi.nlm.nih.gov/pubmed/29953127
work_keys_str_mv AT perezrk adventofcrisprbasedimmunotherapyinhematologicmalignancies
AT chenr adventofcrisprbasedimmunotherapyinhematologicmalignancies
AT kangr adventofcrisprbasedimmunotherapyinhematologicmalignancies
AT perezar adventofcrisprbasedimmunotherapyinhematologicmalignancies